Kiniksa Pharmaceuticals (KNSA) Q3 2026 earnings review
Kiniksa lifts its sales plan past $1B, but trial costs will jump
Kiniksa Pharmaceuticals, the seller of the heart-inflammation drug Arcalyst, grew sales fast and lifted its full-year plan past one billion dollars. Third-quarter revenue rose 58% from a year ago to $286 million as the share of target patients on the drug reached 23%, and operating profit more than doubled on lower research spending. Chief executive Sanj K. Patel raised the 2026 sales outlook, and third-quarter results finished well above what the company's own prior plan pointed to.
| Revenue | $286.0M +58.1% from a year ago |
|---|---|
| Operating margin | 19.0% +5.7 percentage points from a year ago |
| Target patients on Arcalyst | 23% 21% last quarter |
| Full-year revenue outlook | Raised $60M middle of the range: $1.048B (+54.6%) |
⚖️ Verdict: 🟢 Bullish
The story got better because patient additions dispelled fears of a second-half slowdown and pushed the sales outlook up by $60 million. One caution: the company issued its first full-year spending plan for research and overhead, which by our math points to a $50 million cost jump in the fourth quarter.
The question now is whether the fourth-quarter spending jump is a temporary spike from starting two clinical trials or the new normal for 2027. If it is temporary, the third quarter's 19% operating margin shows the business's true earning power; if it is permanent, trial bills will eat up next year's sales gains. Management's 2027 expense outlook on the fourth-quarter report will settle it.
🐂 Bull Case
Arcalyst Adoption Drives Record Quarter and $60M Plan Raise
Arcalyst, a weekly injection for a painful heart inflammation called recurrent pericarditis, brings in all of Kiniksa's sales. Chief executive Sanj K. Patel pointed to "gains in patient and physician adoption" that are "positioning ARCALYST to achieve blockbuster status this year".
- Quarterly revenue: $286.0 million, up 58.1% from a year ago and up $42.4 million from last quarter
- Total prescribers since launch: more than 5,450, adding about 450 doctors for a second straight quarter by our math
- Patient share: about 23% of the 14,000 target patients with multiple flare-ups, up from 21% last quarter
That 2-point gain equals about 280 additional active patients by our math. Because patients stay on the drug for an average of three years, new prescriptions build on top of old ones, so the biopharmaceutical company raised its full-year sales outlook by $60 million at the middle of the range.
What to watch: fourth-quarter revenue against the $303.7 million implied by the full-year outlook. Beating that level would show that typical fourth-quarter insurance discounts did not slow patient additions.
Operating Margin Rebounds as Research Spending Dips
Kiniksa's operating margin expanded by 5.7 percentage points from a year ago to 19.0% in the third quarter, reversing last quarter's drop to 11.2%. Operating profit more than doubled from a year ago to $54.2 million as sales outpaced overhead and trial costs.
Selling and general overhead fell by 4.3 percentage points of revenue from a year ago to 22.9%, and research and development fell by 1.9 percentage points to 11.5% (dropping $8.1 million from last quarter). Those savings more than covered the Regeneron profit split, which rose 2.0 points to 37.0% of sales.
What to watch: fourth-quarter operating margin. Because the new full-year expense plan points to higher spending in the final three months, this quarter's 19.0% margin is likely a temporary peak.
Pipeline Moves Forward With Late-2027 Data Target
Kiniksa is developing two follow-on heart inflammation drugs that it owns outright: KPL-387, a monthly injection, and KPL-1161, a quarterly injection. Patel set a goal of "bringing this important treatment option to patients in the 2028/2029 timeframe" for KPL-387.
The company is enrolling up to 85 patients in PASTORALE, the Phase 3 trial of KPL-387, and now expects results in the second half of 2027. It is also running a Phase 2 study on switching patients from standard treatments, and plans to start human trials of KPL-1161 by year-end.
What to watch: confirmation that the KPL-1161 Phase 1 trial has started by the fourth-quarter report. Starting on time keeps the quarterly dosing candidate on schedule behind KPL-387.
Positives this quarter didn't test
Two commercial drivers from prior quarters received no new figures in the earnings release.
- First-recurrence patient share: previously around 20% of prescriptions; management usually updates this split on the conference call.
- Digital doctor targeting and connected-TV ads: launched earlier in 2026 to speed up diagnoses; no prescription figures from these tools appeared in the release.
🐻 Bear Case
New Spending Plan Points to Fourth-Quarter Cost Jump
Kiniksa issued its first explicit full-year outlook for research and overhead costs, addressing a gap from prior quarters. While third-quarter research spending fell to $32.8 million, the new annual forecast of $160 million to $170 million shows the dip will not last.
- Fourth-quarter research and development implied by the outlook: $63.8 million at the middle of the range, up 84.5% from a year ago by our math
- Fourth-quarter selling and general overhead implied by the outlook: $84.6 million at the middle of the range, up 49.1% from a year ago by our math
Combined fourth-quarter research and overhead costs will jump by $50.3 million from the third quarter by our math, as the PASTORALE trial enrolls and KPL-1161 enters human testing. Because fourth-quarter revenue is set to rise by $17.7 million at the middle of the range, operating profit will shrink in the final quarter.
What to watch: the 2027 research and overhead spending outlook on the fourth-quarter report. It will show whether the fourth-quarter cost jump is a year-end billing spike or the new baseline.
One Drug Split With Regeneron Carries the Entire Business
Arcalyst generates 100% of Kiniksa's revenue ($286.0 million in the third quarter), and the company splits the drug's operating profit evenly with its discoverer, Regeneron. As Arcalyst becomes more profitable, Regeneron's share takes a larger slice of total company revenue.
That collaboration expense reached $105.8 million this quarter, rising from 35.0% of revenue a year ago to 37.0%. Meanwhile, Kiniksa pays 100% of the research bills for KPL-387 ($32.8 million in total research this quarter) to build a wholly owned replacement that will not have Phase 3 data until late 2027.
What to watch: enrollment completion for the 85-patient PASTORALE trial. Any delay pushes back the 2028 to 2029 launch window and leaves the company reliant on split-profit Arcalyst sales.
Risks this quarter didn't answer
Five standing concerns from previous quarters were not addressed in the third-quarter release.
- Commercial plan for selling KPL-387 alongside Arcalyst: still unstated; a transition study is running, but management has not said whether KPL-387 will replace Arcalyst.
- Ceiling on patient share: penetration reached 23% of the 14,000 multiple-flare-up population, with no target cap given.
- Exact treatment duration: reported as "approximately 3 years" for a fourth straight quarter instead of in months, hiding whether patients stay on the drug past three years.
- Phase 2 flare-up counts for KPL-387: still unreleased following last quarter's interim summary.
- Gross-to-net price discount rate: not in the release; the quarterly filing or call will show how much fourth-quarter discounts will rise.
💲 Other KPIs
Cash and short-term investments rose by $42.8 million in the third quarter and by $154.7 million over the first nine months of 2026. The drugmaker carries no debt, and the growing cash pile sits on the balance sheet with no share buyback or acquisition announced.
Working capital — short-term assets minus short-term bills — grew 43.9% from $388.0 million at the end of 2025, and rose $60.9 million from the second quarter. The increase tracks the cash generated by Arcalyst sales.
Diluted shares rose 6.1% from 80.0 million a year ago and 1.8% from 83.4 million last quarter. Employee stock options and share-based pay ($13.1 million this quarter) continue to expand the share count.
🔮 Guidance
Raised. The middle of the range moved up $60 million to 54.6% annual growth. By our math, that leaves $303.7 million for the fourth quarter (50.2% growth from a year ago and a $17.7 million gain from the third quarter). It is the third raise this year, and each was larger than the last: +$27.5M, +$50.0M, +$60.0M.
New. The plan puts full-year research spending at $165 million at the middle of the range, up 70.4% from 2025. By our math, subtracting the $101.2 million spent in the first nine months leaves $63.8 million for the fourth quarter, nearly double the third quarter's $32.8 million.
New. Full-year selling and overhead costs are set to reach $275 million at the middle of the range, up 40.1% from last year. By our math, that leaves $84.6 million for the fourth quarter, up 49.1% from a year ago and up $19.3 million from the third quarter.
Unchanged. The group still expects its operating plan to generate cash for the full year. With cash and short-term investments already up $154.7 million over the first nine months of 2026, it has easily cleared that bar.
❓ Key Questions
Why do research costs nearly double in the fourth quarter?
The new full-year research outlook of $160 million to $170 million leaves about $63.8 million for the fourth quarter, up from $32.8 million in the third quarter. Investors need to know how much of that jump is one-time trial startup costs versus recurring run-rate spending for 2027.
How will Kiniksa sell KPL-387 alongside Arcalyst?
Kiniksa splits Arcalyst profits 50/50 with Regeneron but owns KPL-387 outright. Although the company is running a study on switching patients to KPL-387, management still has not said whether it plans to switch existing Arcalyst patients or keep both drugs on the market.
What was the third-quarter price discount rate?
The earnings release did not include the gross-to-net discount rate, which stood at 7.2% for the first half of the year. Knowing the third-quarter rate and expected fourth-quarter seasonal increase is necessary to judge underlying demand in the implied fourth-quarter sales plan.
Are patients staying on Arcalyst past three years?
For four quarters in a row, the release has stated that average therapy duration is "approximately 3 years" after previously reporting exact months up to 32 months. Reporting the exact month figure would show whether early patients are stopping treatment or staying past the three-year mark.